R_NW
Posted - 1 hour ago
$SLS I just did my proxy votes which were fairly routine with nothing earth shattering. I would like to see the word "Commercialization" come up during their state of the business segment, along with "approved" "break-through-therapy" "expanding" etc. Lots of companies announce new products and innovations during the meeting.
History101
Posted - 1 hour ago
$SLS short interest, per Barron's, 4/30/2024: 6.99MM shares short (up 23% from 4/15/2024) 12.19% of float 4.47 days to cover
DharlMorey2
Posted - 1 hour ago
$SLS When a company has multiple drugs successful (REGAL in phase-3 and coming to a close with no safety concerns), SLS009 (100% effective, in phase-2), then I have little worry with the operations and simply sit back and accumulate for as long as I can. I think the interim analysis (could already be checking data for all we know) is going to to burn those ~7 million short shares and send this to double-digits -- should be fireworks! I have not been able to in the last two months acquire any options contract at the 'ask' -- so the few I have show that no one (even market makers) are willing to write call contracts -- they need there shares. At this price, I've also accumulated 15k shares too -- and I'm not writing any contracts for anyone -- this is going to be a big mover and trending any day now (maybe tomorrow?) in the next month or so. $XBI
neutralUser
Posted - 1 hour ago
$SLS Curious mind: Sellas announcement for June IDMC meeting occurred on April 29th. The same day, Sellas published the proxy material for the annual meeting. So, it is possible that IDMC will meet before the annual meeting and they can announce it on the day. This sounds most logical to me. They wouldn't announce annual meeting if they knew the IDMC meeting after June 20. My guess is June 17-18 is the IDMC meeting. DYOR
Bio_buyout
Posted - 2 hours ago
$SLS I am optimistic that we have some good news coming with Regal being imminent (now over three months). We also have IDMC pushed up a moth or two which is also very encouraging. Also SLS009 seems like it has potential to be a block buster. However, I am very concerned about SELLAS Short Interest Up 23.3% in April. There was a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 6,990,000 shares, an increase of 23.3% from the April 15th total of 5,670,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is presently 4.6 days. I am hoping that this is our time and the shorts will be decimated!
DDGenie
Posted - 2 hours ago
$SLS There are ~77k cases of new AML diagnosed annually and 97% of patients express the Wilms Tumor 1 oncogene. Sellas' drug GPS teaches the immune system how to target the Wilms Tumor 1 antigen and inhibit cancer without causing serious side effects/toxicity concerns. This is due to the fact that the WT1 antigen does not express itself in any significant quantity among healthy organs/tissue. GPS = Longevity + Negligible side-effects = Meaningful Clinical Benefit.
alinbio
Posted - 3 hours ago
$SLS Next Idmc meeting, we may not have 60 deaths. If Bat is 8 months mOS, then you have about 40 If Gps is 25-30 mOS, thats about 10-20 Not quite 60 but enough to halt IMHO They will also have: 1-Complete data on all 128 patients up to May 31 2- Data on subsets such as high risk mutations in each group, secondary endpoints. Many of the regal patients are refractory mutations to Bat such as Eln2017, Tp53, Nras. If these respond well to Gps then that's a home run(like Asxl1 with Sls009) Remember Idmc asked for 'ad hoc data' before, well this info will be all they need to halt My belief is that the Idmc has been looking to halt but did not have enough data to do so till now (June)
cea
Posted - 3 hours ago
@jonnyloitering Fell ya brother. I wish all the threads were like $SLS; would be much better value for all concerned.
jonnyloitering
Posted - 4 hours ago
$SLS Something I find positive and sort of strange about this ticker's thread is the level of discourse. The majority of posts here are a thoughtful and cogent discussion of real information. It's not the normal drivel you find on ST, "Wen moon?" Or inversely,"I'm shorting this to zero." There is, of course, some of that going on, but the quality of thinking here overall is a real positive. Just wanted to say thanks for not being a bunch of dumb asses. Have a happy Sunday and don't spend it here. Personally, I'm going to spend it working on my yard, followed by a bbq with the family.
JakeDelToro
Posted - 4 hours ago
$SLS Annual meeting Thurs June 20.
Friday June 21 option exp. are relatively low OI.
I know Sterg would love to deliver REGAL news on or right before that annual meeting.
Would love to see that line up (and allow me to grab a couple more calls and shares).
Big month fam🤞🏼
JakeDelToro
Posted - 4 hours ago
$SLS Can someone please explain why the IDMC would reschedule their charter scheduled meeting from September to June (3 months early)?
cea
Posted - 5 hours ago
$SLS Technical "sentiment" from my Fidelity Account; hope this is of interest and value...
cea
Posted - 5 hours ago
$SLS Analyst opinions as of today from my Fidelity Account; hope this is of interest and value...
Indy001
Posted - 8 hours ago
$SLS
Cabasada
Posted - 8 hours ago
$SLS can someone explain the OS impact on REGAL study for both BAT and GPS of the inclusion criteria "Patients must have > 300 lymphocytes/ μL"
bikechain
Posted - 8 hours ago
$SLS For those of us who aren’t technically inclined what does (HR <0.54 ) mean in layman’s terms?
Cyrus_C
Posted - 10 hours ago
$SLS no expert here, but we maybe overthinking it. 66 events early March, meaning either death, discontinuation of treatments, completion of treatments, etc. CR2 patients without HCT are not in great condition to start with. And I read somewhere that when they discontinue, they typically have 2-3 months to live. Sad but thats how tough this disease is even with BAT. So 66 early March, 2-3 months and we should hit 60 for IA soon, if not already.
alinbio
Posted - 18 hours ago
$SLS I did some homework The company said they have enough patients for IA and final readout on Oct 12 2023 In Aug they didnt say that, so sometime in sep they had 80 patients. Thats 8 mos ago, hence 40 events from Bat in May given prior mOS of 8 months for Bat (Max) Leaves 20 for Gps, thats a Hr of 0.5 This also means they enrolled pretty slowly the first half of the study
JakeDelToro
Posted - 19 hours ago
$SLS Everyone who is new here (or hasn't listened to this) should truly take 45 mins and give this a listen today or tomorrow. The next 30 trading days for Sellas will be monumental in determining the long term trajectory of the company and it's promising pipeline. Invest 45 mins in your education and listen and learn. The more you know, the more your account will grow! https://viavid.webcasts.com/viewer/event.jsp?ei=1647788&tp_key=4e93ad079f
History101
Posted - 20 hours ago
$SLS golden cross still intact:
alinbio
Posted - 20 hours ago
$SLS Just like Sls009 works 100% in Asxl1 mutations, the regal study will identify subsets of Aml where Gps is far superior to Bat. Gabri from reddit: "We can see that ELN2017 ‘adverse’ profile is present in around 60% of the r/R AML, on average. If this is confirmed also in REGAL, then it would represent a very high proportion of patients not responding to the Aza+Ven combination. There is also a sizeable quota of TP53 and NRAS mutations seen in previous studies (very poor response following Venetoclax) which could represent up to 40% of the total CR2 population in REGAL studies. The same applies to ‘complex cytogenetics’ CR2 population (up to 45% in some studies)."
alinbio
Posted - 20 hours ago
$SLS Good post by Gabri from reddit : Data known: 105 enrolled at the end of Nov 2023 assuming enrollment rate 6/month in the latest period of the trial with India sites pushing through the finish line), we can guessestimate to have had 82 by end of July 2023 (41 per arm) Assuming a BAT mOS of 8 months= 41-42 deaths occurred by end of April 2024 Assuming a GPS mOS of 24 months= 14 deaths occurred by end of April 2024 In total 55-56 deaths (conservative estimates by the end of April 2024) and many relapses (around 12-15) and 2 side effects (3% in BAT arm, see study by Bazinet
G_Trade
Posted - 23 hours ago
$SLS ✅
https://www.reddit.com/r/sellaslifesciences/s/LhQ6IIx7wJ
alinbio
Posted - 23 hours ago
$SLS That is P2 early was 16 months, later was 21 months. Regal is obviously the P3 i am predicting as closer to 30 months. Younger than P2 and some are Mrd negative
alinbio
Posted - 23 hours ago
$SLS The mOS for early Regal Gps was 16 months, and later at 31 months into the study was 21 months. We are now 40 months into the study, i predict a mOS close to 30 months. Look at mOS of 67 months in Cr1 Gps vs 17-25 months for Bat in all ages I also predict we are definitely halting the study at IA
ccx
Posted - 1 day ago
$SLS If you're here already, you're early. Name is virtually undiscovered atm, will change with Ph3 data PR. I seriously think that some of you fail to understand how much you undermine the credibility of the opportunity with trying to attract people with Pollyannaish price targets. Everyone out there nowadays has heard that rhetorical pitch for a hundred different stocks. Stick to the facts when trying to introduce prospects, avoid the 'buy because it's going up 10x'. Obviously, we're here because we believe in that kind of potential but you're really not going to hook any fish worth keeping around with that pitch. They'll run away at the first sign of a loss because they don't have any understanding for the business. Content like that shared by @betbetsgold this morning or the report from 'super-secret Anson short agent' @DDGenie is what we need. Please avoid trying to attract people that don't know this name with "it's mooning" because it's a literal repellant nowadays. JMO. HAGW
bikechain
Posted - 1 day ago
$SLS How often are halts called at the same stage GPS is in now? What percentage?
diamcertsbs
Posted - 1 day ago
$SLS There is certainly a lot of wishful thinking on this board in regard to the price that SLS might rate if this or that happens. Will certainly make a lot of wealthy people if these dreams come true. If all the sufferers of cancers are helped and investors become wealthy or wealthier as the case might be then all will win...The best of both worlds indeed...GL to all....
bikechain
Posted - 1 day ago
$SLS I’d be thrilled with 40.
Beyond thrilled with 80.